ApurvAgrawalMD

Oncology • Brick, NJ

Physician

Join to view full profile

Dr. Agrawal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Agrawal's full profile

Already have an account?

Office
1608 Route 88 West
Suite 250
Brick, NJ 08724
Phone+1 732-840-8880

Fax+1 732-840-3939
Is this information wrong?

Education & Training

Boston University Medical CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
Boston University Medical CenterFellowship, Geriatric Medicine (Internal Medicine), 2006 - 2007
Muhlenberg Regional Medical CenterResidency, Internal Medicine, 2003 - 2006
M. Rampure Medical CollegeClass of 2002

Certifications & Licensure

NJ State Medical License 2005 - 2025
PA State Medical License 2013 - 2016
MA State Medical License 2006 - 2010
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013

Clinical Trials

Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL Start of enrollment: 2014 Jun 01
Terminated
Phase 2
Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients Start of enrollment: 2017 Oct 24
Completed
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML Start of enrollment: 2016 May 01
Recruiting
Phase 2
Roles: Contact

Publications & Presentations

PubMed

3 citations
Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Essential Thrombocythemia Enrolled in the MOST Study.
Abdulraheem Yacoub, Roger M. Lyons, Srdan Verstovsek, Ryan Shao, David Tin Chu, Apurv Agrawal, Smitha Sivaraman, Philomena Colucci, Dilan Paranagama, John Mascarenhas> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 Mar 1

Lectures

Interim Safety and Efficacy of Lower Intensity Induction Therapy with Intravenous Prexigebersen (BP1001) in Patients with Untreated Acute Myeloid Leukemia (AML)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Hospital Affiliations

Hackensack Meridian Health Ocean University Medical CenterBrick, New Jersey
Hackensack Meridian Health Jersey Shore University Medical CenterNeptune, New Jersey
Community Medical CenterToms River, New Jersey
Monmouth Medical Center, Southern CampusLakewood, New Jersey